934660-94-3

Usage

Uses

The (R)-enantiomer of the MEK1 inhibitor XL518 (X746250).

Upstream product

• 934660-67-0 1-[3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl]-3-azetidinone 
• 59192-02-8 (R)-2-bromopiperidine 
• 172229-93-5 (R)-2-chloropiperidine 
• 934665-56-2 tert-butyl 2-(1-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-3-hydroxyazetidin-3-yl)piperidine-1-carboxylate 

Downstream Products

• 934665-57-3 1-({3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}carbonyl)-3-[(2R)-piperidin-2-yl]azetidin-3-ol hydrochloride 

Relevant academic research and scientific papers

Preparation method of cobimetinib

The invention discloses a preparation method of cobimetinib. The preparation method comprises the following steps of (1) performing oxidative coupling cyclization on acetone and ammonia water under the conditions of catalysis by iodized salt and protonic

METHODS OF USING MEK INHIBITORS

The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.